Long-term control of macroprolactinomas

References

• Mindermann T, Wilson CB. Age-related and gender-related occurrence of pituitary adenomas. Clin. Endocrinol. (Oxford)41, 359–364 (1994).
   PubMed Web of Science ®Google Scholar
• Miyai K, Ichibara K, Kondo L, Mori S. Asymptomatic hyperprolactinemia and prolactinoma in the general population mass screening by paired assays of serum prolactin. Clin. Endocrinol. (Oxford)25, 549–554 (1986).
   PubMed Web of Science ®Google Scholar
• Drange MR, Fram NR, Herman-Bonert V, Melmed S. Pituitary tumor registry: a novel clinical resource. J. Clin. Endocrinol. Metab.85, 168–174 (2000).
   PubMed Web of Science ®Google Scholar
• De Menis E, Visentin A, Billeci D et al. Pituitary adenomas in childhood and adolescence. Clinical analysis of 10 cases. J. Endocrinol. Invest.24, 92–97 (2001).
   Google Scholar
• Mah PM, Webster J. Hyperprolactinemia: etiology, diagnosis, and management. Semin. Reprod. Med.20, 365–374 (2002).
   PubMed Web of Science ®Google Scholar
• Poon A, McNeill P, Harper A. Patterns of visual loss associated with pituitary macroadenomas. Aust. NZ J. Ophthalmol.23, 107–115 (1995).
   Google Scholar
• Zikel OM, Atkinson JL, Hurley DL. Prolactinoma manifesting with symptomatic hydrocephalus. Mayo Clin. Proc.74, 475–477 (1999).
   PubMedGoogle Scholar
• Minniti G, Jaffrain-Rea ML, Santoro A et al. Giant prolactinomas presenting as skull base tumors. Surg. Neurol.57, 99–103 (2002).
   Web of Science ®Google Scholar
• Bronstein MD, Musolino NR, Cardim CS , Monteiro M, Marino JR. Treatment of macroprolactinomas with a long-acting, parenteral and repeatable new form of bromocriptine. In: Advances in Pituitary Adenoma Research. Landolt AM, Heitz PU, Zapf J, Girard J, Del Pozo E (Eds). Pergamon Press, Oxford, UK 313–316 (1988).
   Google Scholar
• Bevan JS, Burke CW, Esiri MM, Adams CB. Misinterpretation of prolactin levels leading to management errors in patients with sellar enlargement. Am. J. Med.82, 29–32 (1987).
   PubMed Web of Science ®Google Scholar
• Frieze TW, Mong DP, Koops MK. ‘Hook effect’ in prolactinomas: case report and review of literature. Endocr. Pract.8, 296–303 (2003).
   Google Scholar
• Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. Am. J. Roentgenol.188, 586–592 (2007).
   PubMed Web of Science ®Google Scholar
• Hardy J. Trassphenoidal microsurgery of the normal and pathological pituitary. Clin. Neurosurg.16, 185–217 (1969).
   PubMedGoogle Scholar
• Fluckiger E, Wagner HR. 2-Br-α-ergokryptin: influence on fertility and lactation in the rat. Experientia24, 1130–1131 (1968).
   Google Scholar
• Ben-Jonathan N. Regulation of prolactin secretion. In: The Pituitary Gland. Imura H (Ed.). Raven Press, NY, USA 261 (1994).
   Google Scholar
• Ciccarelli E, Mazza E, Ghigo E et al. Long term treatment with oral single administration of bromocriptine in patients with hyperprolactinemia. J. Endocrinol. Invest.10, 51–53 (1987).
   Google Scholar
• Corenblum B, Webster BR, Mortimer CB et al. Possible antitumour effect of 2 bromoergocryptine in 2 patients with large prolactin-secreting pituitary adenomas. Clin. Res.23, 614A (1975).
   Google Scholar
• Molitch ME, Elton RL, Blackwell RE et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J. Clin. Endocrinol. Metab.60, 698–705 (1985).
   PubMed Web of Science ®Google Scholar
• Essais O, Bouguerra R, Hamzaoui J et al. Efficacy and safety of bromocriptine in the treatment of macroprolactinomas. Ann. Endocrinol. (Paris)63, 524–531 (2002).
   PubMedGoogle Scholar
• Shrivastava RK, Arginteanu MS, King WA, Post KD. Giant prolactinomas: clinical management and long-term follow up. J. Neurosurg.97, 299–306 (2002).
   PubMed Web of Science ®Google Scholar
• Bronstein M, Musolino N, Cunha-Neto M, Marino JR. Hyperprolactinemia therapy: lessons learned from long-term follow-up. Eur. J. Endocrinol.130, 116 (1994).
   Google Scholar
• Bronstein MD. Prolactinoma in men. Arq. Bras. Endocrinol. Metab.43, 338 (1999).
   Google Scholar
• De Rosa M, Colao A, Di Sarno A. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur. J. Endocrinol.138, 286–293 (1998).
   PubMed Web of Science ®Google Scholar
• Kleinberg DL, Boyd AE 3rd, Wardlaw S et al. Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone. N. Engl. J. Med.309, 704–709 (1983).
   Google Scholar
• Blackwell RE, Bradley EL Jr, Kline LB et al. Comparison of dopamine agonists in the treatment of hyperprolactinemic syndromes: a multicenter study. Fertil. Steril.39, 744–748 (1983).
   Google Scholar
• Ahmed SR, Shalet SM. Discordant responses of prolactinoma to two different dopamine agonists. Clin. Endocrinol. (Oxford)24, 421–426 (1986).
   PubMed Web of Science ®Google Scholar
• Lamberts SW, Quik RF. A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia. J. Clin. Endocrinol. Metab.72, 635–634 (1991).
   PubMed Web of Science ®Google Scholar
• Berezin M, Avidan D, Baron E. Long-term pergolide treatment of hyperprolactinemic patients previously unsuccessfully treated with dopaminergic drugs. Isr. J. Med. Sci.27, 375–379 (1991).
   PubMedGoogle Scholar
• Freda PU, Andreadis CI, Khandji AG et al. Long-term treatment of prolactin-secreting macroadenomas with pergolide. J. Clin. Endocrinol. Metab.85, 8–13 (2000).
   Google Scholar
• Orrego JJ, Chandler WF, Barkan AL. Pergolide as primary therapy for macroprolactinomas. Pituitary3, 251–256 (2000).
   Google Scholar
• Van Camp G, Flamez A, Cosyns B et al. Heart valvular disease in patients with Parkinson’s disease treated with high-dose pergolide. Neurology61, 859–861 (2003).
   PubMed Web of Science ®Google Scholar
• Vance ML, Lipper M, Klibanski A et al. Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205–502. Ann. Intern. Med.112, 668–673 (1990).
   PubMed Web of Science ®Google Scholar
• Serri O, Beauregard H, Lesage J et al. Long term treatment with CV 205–502 in patients with prolactin-secreting pituitary macroadenomas. J. Clin. Endocrinol. Metab.71, 682–687 (1990).
   PubMed Web of Science ®Google Scholar
• van der Lely AJ, Brownell J, Lamberts SW. The efficacy and tolerability of CV 205–502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine. J. Clin. Endocrinol. Metab.72, 1136–1141 (1991).
   PubMed Web of Science ®Google Scholar
• Kvistborg A, Halse J, Bakke S et al. Long-term treatment of macroprolactinomas with CV 205–502. Acta Endocrinol. (Copenhagen)128, 301–307 (1993).
   Google Scholar
• Glaser B, Nesher Y, Barziliai S. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205–502. J. Reprod. Med.39, 449–454 (1994).
   Google Scholar
• Del Dotto P, Bonuccelli U. Clinical pharmacokinetics of cabergoline. Clin. Pharmacokinet42, 633–645 (2003).
   PubMed Web of Science ®Google Scholar
• Ferrari C, Paracchi A, Mattei AM, de Vincentiis S, D’Alberton A, Crosignani P. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol. (Copenhagen)126, 489–494 (1992).
   PubMedGoogle Scholar
• Biller BM, Molitch ME, Vance ML et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J. Clin. Endocrinol. Metab.81, 2338–2343 (1996).
   PubMed Web of Science ®Google Scholar
• De Rosa M, Ciccarelli A, Zarrilli S et al. The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males. Clin. Endocrinol. (Oxford)64, 307–313 (2006).
   PubMed Web of Science ®Google Scholar
• Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N. Engl. J. Med.331, 904–909 (1994).
   PubMed Web of Science ®Google Scholar
• Rengachary SS, Tomita T, Jefferies BF, Watanabe I. Structural changes in human pituitary tumor after bromocriptine therapy. Neurosurgery10, 242–251 (1982).
   Google Scholar
• Tindall GT, Kovacs K, Horvath E, Thorner MO. Human prolactin-producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study. J. Clin. Endocrinol. Metab.55, 178–183 (1982).
   Google Scholar
• Lloyd HM, Jacobi JM, Willgoss DA. DNA synthesis by pituitary tumours, with reference to plasma hormone levels and to effects of bromocriptine. Clin. Endocrinol. (Oxford)43, 79–85 (1995).
   Google Scholar
• Gruszka A, Pawlikowski M, Kunert-Radek J. Anti-tumoral action of octreotide and bromocriptine on the experimental rat prolactinoma: anti-proliferative and pro-apoptotic effects. Neuroendocrinol. Lett.22, 343–348 (2001).
   Google Scholar
• Kovacs K, Stefaneanu L, Horvath E et al. Effect of dopamine agonist medication on prolactin producing pituitary adenomas. A morphological study including immunocytochemistry, electron microscopy and in situ hybridization. Virchows Arch. A Pathol. Anat. Histopathol.418, 439–446 (1991).
   Google Scholar
• Thorner MO, Perryman RL, Rogol AD et al. Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine. J. Clin. Endocrinol. Metab.53, 480–483 (1981).
   PubMed Web of Science ®Google Scholar
• Orrego JJ, Chandler WF, Barkan AL. Rapid re-expansion of a macroprolactinoma after early discontinuation of bromocriptine. Pituitary3, 189–192 (2000).
   Google Scholar
• Johnston DG, Hall K, Kendall-Taylor P, Patrick D, Watson M, Cook DB. Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography. Lancet2, 187–192 (1984).
   PubMed Web of Science ®Google Scholar
• van ‘t Verlaat JW, Croughs RJ. Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size. Clin. Endocrinol. (Oxford)34, 175–178 (1991).
   Google Scholar
• Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr. Rev.13, 220–240 (1992).
   PubMed Web of Science ®Google Scholar
• Molitch ME. Medical management of prolactin-secreting pituitary adenomas. Pituitary5, 55–65 (2002).
   PubMedGoogle Scholar
• Colao A, Di Sarno A, Landi ML et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J. Clin. Endocrinol. Metab.85, 2247–2252 (2000).
   PubMed Web of Science ®Google Scholar
• Warfield A, Finkel DM, Schatz NJ, Savino PJ, Snyder PJ. Bromocriptine treatment of prolactin-secreting pituitary adenomas may restore pituitary function. Ann. Intern. Med.101, 783–785 (1984).
   Google Scholar
• George LD, Nicolau N, Scanlon MF, Davies JC. Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas. Clin. Endocrinol. (Oxford)53, 595–599 (2000).
   PubMed Web of Science ®Google Scholar
• Sibal L, Ugwu P, Kendall-Taylor P et al. Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function. Pituitary5, 243–246 (2002).
   Google Scholar
• Passos VQ, Souza JJ, Musolino NR, Bronstein MD. Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J. Clin. Endocrinol. Metab.87, 3578–3582 (2002).
   Google Scholar
• Ferrari C, Paracchi A, Mattei AM, de Vincentiis S, D’Alberton A, Crosignani P. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol. (Copenhagen)126, 489–494 (1992).
   PubMedGoogle Scholar
• Cannavo S, Curto L, Squadrito S, Almoto B, Vieni A, Trimarchi F. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J. Endocrinol. Invest.22, 354–359 (1999).
   Google Scholar
• Muratori M, Arosio M, Gambino G, Romano C, Biella O, Faglia G. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J. Endocrinol. Invest.20, 537–46 (1997).
   PubMed Web of Science ®Google Scholar
• Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N. Engl. J. Med.349, 2023–2033 (2003).
   PubMed Web of Science ®Google Scholar
• Gen M, Uozumi T, Ohta M, Ito A, Kajiwara H, Mori S. Necrotic changes in prolactinomas after long term administration of bromocriptine. J. Clin. Endocrinol. Metab.59, 463–470 (1984).
   PubMed Web of Science ®Google Scholar
• Koppelman MC, Jaffe MJ, Rieth KG, Caruso RC, Loriaux DL. Hyperprolactinemia, amenorrhea, and galactorrhea. A retrospective assessment of twenty-five cases. Ann. Intern. Med.100, 115–121 (1984).
   PubMed Web of Science ®Google Scholar
• Sisam DA, Sheehan JP, Sheeler LR. The natural history of untreated microprolactinomas. Fertil. Steril.48, 67–71 (1987).
   PubMed Web of Science ®Google Scholar
• Karunakaran S, Page RC, Wass JA. The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin. Endocrinol. (Oxford)54, 295–300 (2001).
   PubMed Web of Science ®Google Scholar
• Pinto G, Zerah M, Trivin C, Brauner R. Pituitary apoplexy in an adolescent with prolactin-secreting adenoma. Horm. Res.50, 38–41 (1998).
   PubMedGoogle Scholar
• Turner TH, Cookson JC, Wass JA, Drury PL, Price PA, Besser GM. Psychotic reactions during treatment of pituitary tumours with dopamine agonists. Br. Med. J.289, 1101–1103 (1984).
   PubMed Web of Science ®Google Scholar
• Kains JP, Hardy JC, Chevalier C, Collier A. Retroperitoneal fibrosis in two patients with Parkinson’s disease treated with bromocriptine. Acta Clin. Belg.45, 306–310 (1990).
   PubMed Web of Science ®Google Scholar
• Liuzzi A, Dallabonzana D, Oppizzi G et al. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N. Engl. J. Med.313, 656–659 (1985).
   PubMed Web of Science ®Google Scholar
• Merola B, Colao A, Caruso E et al. Effectiveness and long-term tolerability of the slow release oral form of bromocriptine on tumoral and non-tumoral hyperprolactinemia. J. Endocrinol. Invest.15, 173–176 (1992).
   PubMedGoogle Scholar
• Jasonni VM, Raffelli R, de March A, Frank G, Flamigni C. Vaginal bromocriptine in hyperprolactinemic patients and puerperal women. Acta Obstet. Gynecol. Scand.70, 493–495 (1991).
   PubMed Web of Science ®Google Scholar
• Pascal-Vigneron V, Weryha G, Bosc M, Leclere J. Hyperprolactinemic amenorrhea:treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study. Presse Méd.24, 753–757 (1995).
   PubMedGoogle Scholar
• Verhelst J, Abs R, Maiter D et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J. Clin. Endocrinol. Metab.84, 2518–2252 (1999).
   PubMed Web of Science ®Google Scholar
• Musolino NR, Cunha Neto MB, Bronstein MD. Cabergoline as an alternative for the medical treatment of prolactinomas: experience in bromocriptine intolerance/resistance. Arq. Bras. Endocrinol. Metab.44, 139–143 (2000).
   Google Scholar
• Sabuncu T, Arikan E, Tasan E, Hatemi H. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. Intern. Med.40, 857–861 (2001).
   Google Scholar
• Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac valve regurgitation. N. Engl. J. Med.356, 29–38 (2007).
   PubMed Web of Science ®Google Scholar
• Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N. Engl. J. Med.356, 39–46 (2007).
   PubMed Web of Science ®Google Scholar
• Kupersmith MJ, Kleinberg D, Warren FA, Budzilovitch G, Cooper P. Growth of prolactinoma despite lowering of serum prolactin by bromocriptine. Neurosurgery24, 417–423 (1989).
   Google Scholar
• Jones SE, James RA, Hall K, Kendall-Taylor P. Optic chiasmal herniation – an under recognized complication of dopamine agonist therapy for macroprolactinoma. Clin. Endocrinol. (Oxford)53, 529–534 (2000).
   PubMed Web of Science ®Google Scholar
• Barlas O, Bayindir C, Hepgul K et al. Bromocriptine-induced cerebrospinal fluid fistula in patients with macroprolactinomas: report of three cases and a review of the literature. Surg. Neurol.41, 486–469 (1994).
   PubMedGoogle Scholar
• Bronstein MD, Musolino NR, Benabou S, Marino R Jr. Cerebrospinal fluid rhinorrhea occurring in long-term bromocriptine treatment for macroprolactinomas. Surg. Neurol.32, 346–349 (1989).
   PubMedGoogle Scholar
• Brue T, Pellegrini I, Priou A, Morange I, Jaquet P. Prolactinomas and resistance to dopamine agonists. Horm. Res.38, 84–89 (1992).
   Google Scholar
• Pellegrini I, Rasolonjanahary R, Gunz G et al. Resistance to bromocriptine in prolactinomas. J. Clin. Endocrinol. Metab.69, 500–509 (1989).
   PubMed Web of Science ®Google Scholar
• Caccavelli L, Feron F, Morange I et al. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology60, 314–322 (1994).
   PubMed Web of Science ®Google Scholar
• Friedman E, Adams EF, Hoog A et al. Normal structural dopamine type 2 receptor gene in prolactin-secreting and other pituitary tumors. J. Clin. Endocrinol. Metab.78, 568–574 (1994).
   PubMed Web of Science ®Google Scholar
• Delgrange E, Crabbe J, Donckier J. Late development of resistance to bromocriptine in a patient with macroprolactinoma. Horm. Res.49, 250–253 (1998).
   PubMed Web of Science ®Google Scholar
• Pernicone PJ, Scheithauer BW, Sebo TJ et al. Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer79, 804–812 (1997).
   PubMed Web of Science ®Google Scholar
• Brue T, Pellegrini I, Gunz G et al. Effects of the dopamine agonist CV 205–502 in human prolactinomas resistant to bromocriptine. J. Clin. Endocrinol. Metab.74, 577–584 (1992).
   PubMed Web of Science ®Google Scholar
• Morange I, Barlier A, Pellegrini I, Brue T, Enjalbert A, Jaquet P. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. Eur. J. Endocrinol135, 413–420 (1996).
   Google Scholar
• Colao A, Di Sarno A, Sarnacchiaro F et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J. Clin. Endocrinol. Metab.82, 876–883 (1997).
   PubMed Web of Science ®Google Scholar
• Cho DY, Liau WR. Comparison of endonasal endoscopic surgery and sublabial microsurgery for prolactinomas. Surg. Neurol.58, 371–375 (2002).
   PubMedGoogle Scholar
• Ciric I, Ragin A, Baumgartner C, Pierce D. Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery40, 225–236 (1997).
   PubMed Web of Science ®Google Scholar
• Laws ER Jr, Thapar K. Pituitary surgery. Endocrinol. Metab. Clin. North Am.28, 119–131 (1999).
   PubMed Web of Science ®Google Scholar
• Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results. Neurosurgery44, 254–261 (1999).
   PubMed Web of Science ®Google Scholar
• Losa M, Mortini P, Barzaghi R, Gioia L, Giovanelli M. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J. Clin. Endocrinol. Metab87, 3180–3186 (2002).
   PubMed Web of Science ®Google Scholar
• Molitch ME. Disorders of prolactin secretion. Endocrinol. Metab. Clin. North Am.30, 585–610 (2001).
   PubMedGoogle Scholar
• Landolt AM, Keller PJ, Froesch ER, Mueller J. Bromocriptine: does it jeopardise the result of later surgery for prolactinomas? Lancet2, 657–658 (1982).
   PubMed Web of Science ®Google Scholar
• Soule SG, Farhi J, Conway GS, Jacobs HS, Powell M. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy. Clin. Endocrinol. (Oxford)44, 711–716 (1996).
   Google Scholar
• Marino Jr R, Bronstein MD. The role of pituitary surgery in the treatment of prolactinomas. In: Clinical Endocrinology. Meirelles RMR, Machado A, Povoa LC (Eds). Excepta Medica, Amsterdam, The Netherlands 53–56 (1988).
   Google Scholar
• Perrin G, Treluyer C, Trouillas J, Sassolas G, Goutelle A. Surgical outcome and pathological effects of bromocriptine preoperative treatment in prolactinomas. Pathol. Res. Pract.187, 587–592 (1991).
   Google Scholar
• Serri O, Rasio E, Beauregard H, Hardy J, Somma M. Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N. Engl. J. Med.309, 280–283 (1983).
   PubMed Web of Science ®Google Scholar
• Schlechte JA, Sherman BM, Chapler FK, VanGilder J. Long term follow-up of women with surgically treated prolactin-secreting pituitary tumors. J. Clin. Endocrinol. Metab.62, 1296–1301 (1986).
   PubMed Web of Science ®Google Scholar
• Amar AP, Couldwell WT, Chen JC, Weiss MH. Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery. J. Neurosurg97, 307–314 (2002).
   PubMed Web of Science ®Google Scholar
• Maira G, Anile C, De Marinis L, Barbarino A. Prolactin-secreting adenomas: surgical results and long-term follow-up. Neurosurgery24, 736–743 (1989).
   Google Scholar
• da Motta LA, de Mello PA, de Lacerda CM, Neto AP, da Motta LD, Filho MF. Pituitary apoplexy. Clinical course, endocrine evaluations and treatment analysis. J. Neurosurg. Sci.43, 25–36 (1999).
   PubMedGoogle Scholar
• Tsang RW, Brierley JD, Panzarella T, Gospodarowicz MK, Sutcliffe SB, Simpson WJ. Role of radiation therapy in clinical hormonally-active pituitary adenomas. Radiother. Oncol.41, 45–53 (1996).
   PubMed Web of Science ®Google Scholar
• Molitch ME. Pathologic hyperprolactinemia. Endocrinol. Metab. Clin. North Am.21, 877–901 (1992).
   PubMed Web of Science ®Google Scholar
• Johnston DG, Hall K, Kendall-Taylor P et al. The long-term effects of megavoltage radiotherapy as sole or combined therapy for large prolactinomas: studies with high definition computerized tomography. Clin. Endocrinol. (Oxford)24, 675–685 (1986).
   Google Scholar
• Tsagarakis S, Grossman A, Plowman PN et al. Megavoltage pituitary irradiation in the management of prolactinomas: long-term follow-up. Clin. Endocrinol. (Oxford)34, 399–406 (1991).
   PubMed Web of Science ®Google Scholar
• Brada M, Ajithkumar TV, Minniti G. Radiosurgery for pituitary adenomas. Clin. Endocrinol. (Oxford)61(5), 531–543 (2004)
   PubMed Web of Science ®Google Scholar
• Landolt AM, Lomax N. γ knife radiosurgery for prolactinomas. J. Neurosurg.93, 14–18 (2000).
   PubMedGoogle Scholar
• Pan L, Zhang N, Wang EM et al. γ knife radiosurgery as a primary treatment for prolactinomas. J. Neurosurg.93, 10–13 (2000).
   PubMedGoogle Scholar
• Gemzell C, Wang CF. Outcome of pregnancy in women with pituitary adenoma. Fertil. Steril.31, 363–732 (1979).
   PubMed Web of Science ®Google Scholar
• Molitch ME. Pregnancy and the hyperprolactinemic woman. N. Engl. J. Med.312, 1364–1370 (1985).
   PubMed Web of Science ®Google Scholar
• Bronstein MD. Prolactinomas and pregnancy. Pituitary8, 31–38 (2005).
   Google Scholar
• Holmgren U, Bergstrand G, Hagenfeldt K et al. Women with prolactinoma – effect of pregnancy and lactation on serum prolactin and on tumour growth. Acta Endocrinol. (Copenhagen)111, 452–459 (1986).
   PubMedGoogle Scholar
• van Roon E, van der Vijver JCM, Gerretsen G et al. Rapid regression of a suprasellar extending prolactinoma after bromocriptine treatment during pregnancy. Fertil. Steril.36, 173–177 (1981).
   PubMed Web of Science ®Google Scholar
• Crosignani PG, Ferrari C, Scarduelli C et al. Spontaneous and induced pregnancies in hyperprolactinemic women. Obstet. Gynecol.58, 708–713 (1981).
   PubMed Web of Science ®Google Scholar
• Krupp P, Monka C. Bromocriptine in pregnancy: safety aspects. Klin. Wochenschr.65, 823–827 (1987).
   PubMedGoogle Scholar
• Konopka P, Raymond JP, Merceron RE et al. Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas. Am. J. Obstet Gynecol.146, 935–938 (1983).
   PubMed Web of Science ®Google Scholar
• Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf.14, 228–238 (1996).
   PubMed Web of Science ®Google Scholar
• Robert E, Musatti L, Piscitelli G et al. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod. Toxicol.10, 333–337 (1996).
   PubMed Web of Science ®Google Scholar
• Ricci E, Parazzini F, Motta T et al. Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod. Toxicol.16, 791–793 (2002).
   PubMed Web of Science ®Google Scholar
• Colao A, Abs R, Bárcena DG et al. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin. Endocrinol. (Oxford)68, 66–71 (2008).
   PubMed Web of Science ®Google Scholar
• Badawy SZ, Marziale JC, Rosenbaum AE et al. The long-term effects of pregnancy and bromocriptine treatment on prolactinomas – the value of radiologic studies. Early Pregnancy3, 306–311 (1997).
   Google Scholar
• Peillon F, Racadot J, Moussy D et al. Prolactin-secreting adenomas. A correlative study of morphological and clinical data. In: Treatment of Pituitary Adenomas. Fahlbusch R, Von Werder K (Eds). Thieme, Stuttgart, Germany 114 (1978).
   Google Scholar
• Corenblum B, Donovan L. The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil. Steril.59, 671–673 (1993).
   PubMed Web of Science ®Google Scholar
• Testa G, Vegetti W, Motta T et al. Two-year treatment with oral contraceptives in hyperprolactinemic patients. Contraception58, 69–73 (1998).
   PubMedGoogle Scholar
• Touraine P, Deneux C, Plu-Bureau G, Mauvais-Jarvis P, Kuttenn F. Hormonal replacement therapy in menopausal women with a history of hyperprolactinemia. J. Endocrinol. Invest.21, 732–736 (1998).
   Google Scholar
• Christin-Maître S, Delemer B, Touraine P, Young J. Prolactinoma and estrogens: pregnancy, contraception and hormonal replacement therapy. Ann. Endocrinol. (Paris)68, 106–112 (2007).
   Google Scholar
• Gillam MP, Middler S, Freed DJ, Molitch ME. The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. J. Clin. Endocrinol. Metab.87, 4447–4451 (2002).
   PubMedGoogle Scholar
• Bronstein MD, Knoepfelmacher M, Liberman B, Marino R Jr, Germek OA, Schally AV. Absence of suppressive effect of somatostatin on prolactin levels in patients with hyperprolactinemia. Horm. Metab. Res.19, 271–274, (1987).
   Google Scholar
• Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J. Clin. Invest.100, 2386–2392 (1997).
   PubMed Web of Science ®Google Scholar
• Jaquet P, Ouafik L, Saveanu A et al. Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J. Clin. Endocrinol. Metab.84, 3268–3276 (1999).
   PubMed Web of Science ®Google Scholar
• Hofland LJ, van der Hoek J, van Koetsveld PM et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone and prolactin-secreting pituitary adenomas in vitro. J. Clin. Endocrinol. Metab.89, 1577–1585 (2004).
   PubMed Web of Science ®Google Scholar
• Ren SG, Kim S, Taylor J et al. Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligant. J. Clin. Endocrinol. Metab.88, 5414–5421 (2003).
   PubMed Web of Science ®Google Scholar
• Missale C, Boroni F, Losa M et al. Nerve growth factor suppresses the transforming phenotype of human prolactinomas. Proc. Natl Acad. Sci. USA90, 7961–7965 (1993).
   PubMed Web of Science ®Google Scholar
• Missale C, Losa M, Boroni F, Giovanelli M, Balsari A, Spano PF. Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas. Br. J. Cancer72, 1397–1399 (1995).
   Google Scholar
• Ishikawa H, Heaney AP, Yu R, Horwitz GA, Melmed S. Human pituitary tumor-transforming gene induces angiogenesis. J. Clin. Endocrinol. Metab.86, 867–874 (2001).
   PubMedGoogle Scholar
• Heaney AP, Fernando M, Melmed S. Functional role of estrogen in pituitary tumor pathogenesis. J. Clin. Invest.109, 277–283 (2002).
   PubMed Web of Science ®Google Scholar
• Neff LM, Weil M, Cole A et al. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary10, 81–86 (2007).
   Google Scholar
• Kovacs K, Horvath E, Syro LV et al. Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Hum. Pathol.38, 185–189 (2007).
   PubMed Web of Science ®Google Scholar
• Fadul CE, Kominsky AL, Meyer LP et al. Long-term response of pituitary carcinoma to temozolomide. Report of two cases. J. Neurosurg.105, 621–626 (2006).
   PubMed Web of Science ®Google Scholar
• Kulke M, Stuart K, Enzinger P et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J. Clin. Oncol.24, 401–406 (2006).
   PubMed Web of Science ®Google Scholar
• Nagasubramanian R, Dolan M. Temozolomide: realizing the promise and potential. Curr. Opin. Oncol.15, 412–418 (2003).
   PubMedGoogle Scholar
• Goffin V, Bernichtein S, Touraine P, Kelly PA. Development and potential clinical uses of human prolactin receptor antagonists. Endocr. Rev.26, 400–422 (2005).
   PubMed Web of Science ®Google Scholar
• Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Clin. Endocrinol. (Oxford)67(2), 310–315 (2007).
   PubMed Web of Science ®Google Scholar